Treatment of endometriosis with the antiprogesterone mifepristone (RU486)
Open accessThe DOI matches its Crossref record; 24 of the 28 references it cites were found in a registry or an index.
Abstract
Objective To evaluate the safety and efficacy of an antiprogesterone (mifepristone, RU486; Roussel-Uclaf, Romaineville, France) on endometriosis.Design An open, prospective clinical trial.Setting The clinical practice of an academic faculty.Patients Nine women with endometriosis were studied.Interventions RU486 (50 mg/d) was administered for 6 months.Main outcome measures Daily symptom inventories and urinary steroid metabolites were assessed before, during, and after treatment. Blood for hormone analysis was obtained weekly for 4 weeks and monthly thereafter. The extent of endometriosis, bone mineral density, circadian rhythm of cortisol, and LH pulsatility were determined before and after treatment. Safety laboratory measurements were made before and at 1, 2, and 6 months of treatment.Results Pelvic pain and uterine cramping improved in all patients. Endometriosis regressed by 55%. All patients exhibited endocrine features of anovulatory amenorrhea without hypoestrogenism. A rise in serum LH and T levels was observed during the first month of treatment and one patient developed an elevation of liver transaminases during the last month of treatment. All other measurements were unchanged.Conclusion RU486 appears to be effective in improving the symptoms and causing regression of endometriosis in the absence of significant side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mifepristone-induced regression of endometriotic lesions has been variable and appears to be dependent on the duration of treatment [265, 266].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [266]
In the citing paper
“Mifepristone also reduces lesion size in animal models and patients (Kettel et al., 1996;Mei et al., 2010).”
From Endometriosis and nuclear receptors (2019) · cites this paper as Kettel et al., 1996
Citations
Cites
Revised American Fertility Society Classification of Endometriosis: 1985
(1985) · Fertility and Sterility · doi:10.1016/s0015-0282(16)48430-x · Cited by 1,803
Olive, D. L., & Schwartz, L. B. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282407 · Cited by 675
Contragestion and Other Clinical Applications of RU 486, an Antiprogesterone at the Receptor
Baulieu, E.-E. (1989) · Science · doi:10.1126/science.2781282 · Cited by 483
Stephen Charnock-Jones, D., Sharkey, A. M., Rajput-Williams, J., Burch, D., Paul Schofield, J., Fountain, S. A., Boocock, C. A., & Smith, S. K. (1993) · Biology of Reproduction · doi:10.1095/biolreprod48.5.1120 · Cited by 445
Munro, C. J., Stabenfeldt, G. H., Cragun, J. R., Addiego, L. A., Overstreet, J. W., & Lasley, B. L. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.6.838 · Cited by 422
Dlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy, A. A., Kettel, L. M., Morales, A. J., Roberts, V. J., & Yen, S. S. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.2.8432797 · Cited by 247
Self-citationSilvestre, L., Dubois, C., Renault, M., Rezvani, Y., Baulieu, E.-E., & Ulmann, A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199003083221001 · Cited by 187
Self-citationLessey, B. A., Metzger, D. A., Haney, A. F., & McCarty, K. S. (1989) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60545-9 · Cited by 176
LIU, J. H., GARZO, G., MORRIS, S., STUENKEL, C., ULMANN, A., & YEN, S. S. C. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-6-1135 · Cited by 157
Self-citation
Research works printed but not linked: 1
- Veldhuis, 1988, A novel general biophysical model for simulating episodic endocrine signaling, Am J Physiol, 255, E749
Cited by
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Marquardt, R. M., Kim, T. H., Shin, J.-H., & Jeong, J.-W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153822 · Cited by 491
RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses
Cadepond, P., Ulmann, M., & Baulieu, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.129 · Cited by 424
Self-citation
Metadata
- Authors
- Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C.
- Affiliations
- Université Paris-Sud (FR)
- ORCID
- Baulieu, Etienne E.
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 1996-01
- Volume
- 65
- Issue
- 1
- Pages
- 23-28
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W1910306760
- Cited by
- 216
- References
- 28
- Citations by year
- 2026: 3 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 10 · 2020: 3 · 2019: 9 · 2018: 12 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 8 · 2013: 8 · 2012: 8
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 9643 d)
- Locations
- Fertility and Sterility (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (M-01RR00827, M01RR000827)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- endometriosis, mifepristone, RU486, pelvic pain, luteinizing hormone, testosterone, bone mineral density, diurnal cortisol rhythm, liver transaminases, drug safety
- MeSH terms
- Adolescent, Adult, Endometriosis, Estrone, Female, Hormone Antagonists, Humans, Luteinizing Hormone, Progesterone, Prospective Studies, Mifepristone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). https://app.cochat.ai/papers/10.1016/s0015-0282(16)58022-4
- The paper
- Michael Kettel, L., Murphy, A. A., Morales, A. J., Ulmann, A., Baulieu, E. E., & Yen, S. S. C. (1996). Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertility and Sterility. https://doi.org/10.1016/s0015-0282(16)58022-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.